Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X

Antonios, Gregory; Borgers, Henning; Richard, Bernhard C.; Brauß, Andreas; Meißner, Julius; Weggen, Sascha; Pena, Vladimir; Pillot, Thierry; Davies, Sarah L.; Bakrania, Preeti; Matthews, David; Brownlees, Janet; Bouter, Yvonne; Bayer, Thomas A.

doi:10.1038/srep17338

Download PDF

Article
Open access
Published: 02 December 2015

Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X

Gregory Antonios¹^na1,
Henning Borgers¹^na1,
Bernhard C. Richard¹^na1,
Andreas Brauß¹^na1,
Julius Meißner¹^na1,
Sascha Weggen²^na1,
Vladimir Pena³^na1,
Thierry Pillot⁴^na1,
Sarah L. Davies⁵^na1,
Preeti Bakrania⁵^na1,
David Matthews⁵^na1,
Janet Brownlees⁵^na1,
Yvonne Bouter¹^na1 &
…
Thomas A. Bayer¹^na1

Scientific Reports volume 5, Article number: 17338 (2015) Cite this article

4582 Accesses
35 Citations
29 Altmetric
Metrics details

Subjects

Abstract

Full-length Aβ1-42 and Aβ1-40, N-truncated pyroglutamate Aβ3-42 and Aβ4-42 are major variants in the Alzheimer brain. Aβ4-42 has not been considered as a therapeutic target yet. We demonstrate that the antibody NT4X and its Fab fragment reacting with both the free N-terminus of Aβ4-x and pyroglutamate Aβ3-X mitigated neuron loss in Tg4-42 mice expressing Aβ4-42 and completely rescued spatial reference memory deficits after passive immunization. NT4X and its Fab fragment also rescued working memory deficits in wild type mice induced by intraventricular injection of Aβ4-42. NT4X reduced pyroglutamate Aβ3-x, Aβx-40 and Thioflavin-S positive plaque load after passive immunization of 5XFAD mice. Aβ1-x and Aβx-42 plaque deposits were unchanged. Importantly, for the first time, we demonstrate that passive immunization using the antibody NT4X is therapeutically beneficial in Alzheimer mouse models showing that N-truncated Aβ starting with position four in addition to pyroglutamate Aβ3-x is a relevant target to fight Alzheimer’s disease.

Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease

Article Open access 08 December 2021

Thomas A. Bayer

Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life

Article 16 November 2020

Ruth E. Uhlmann, Christine Rother, … Mathias Jucker

Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future

Article Open access 30 June 2023

Yun Zhang, Huaqiu Chen, … Weihong Song

Introduction

The discovery that certain early-onset familial forms of Alzheimer disease (AD) appear to be caused by an enhanced precipitation of Aβ peptides led to the hypothesis that amyloidogenic Aβ is intimately involved in the AD pathogenic process¹. There is evidence that the primary pathology in AD is triggered by oligomeric species and β-sheet containing amyloid fibrils derived from full-length Aβ_1-42^2,3,4,5. Numerous variants of Aβ_1-42 oligomers have been discussed as pathological factors in AD (reviewed in⁶). We have recently pointed out that the biophysical characteristics of Aβ_1-42 oligomers prefer aggregation into inert amyloid plaques in contrast to N-truncated Aβ_4-42 and pyroglutamate Aβ_3-42 (Aβ_pE3-42) peptides having a higher tendency to stay soluble and maintaining their toxic profile for a longer time period^7,8. Although Aβ_4-42 is highly abundant in AD brains and was discovered as the first N-truncated peptide⁹ its possible role in AD pathology has been largely overlooked. Among different Aβ species present in AD plaques, Lewis et al.¹⁰ demonstrated that Aβ_4-42 is an abundant species in AD, aged controls and vascular dementia patients. Using immunoprecipitation in combination with mass spectrometry, Portelius and colleagues¹¹ corroborated these findings, reporting that Aβ_4-42 belong to one of the major species in the hippocampus and cortex of AD patients. N-terminal deletions, including Aβ_4-42, enhance generation of soluble Aβ oligomers¹². In vitro and in vivo exposure indicated that Aβ_4-42 is as toxic as Aβ_pE3-42 and Aβ_1-42. Expression of Aβ_4-42 in the brain of transgenic mice (Tg4-42 transgenic line) induced a massive CA1 pyramidal neuron loss in the hippocampus without any plaque formation correlating with age-dependent spatial reference memory deficits¹³.

Schenk et al.¹⁴ introduced active immunization as a therapeutic option for AD. APP transgenic mice were immunized with pre-aggregated Aβ_1-42 preventing the development of plaque formation and astrogliosis. Moreover, vaccination also protected transgenic mice from learning and age-related memory deficits¹⁵. Many immunization trials in symptomatic AD patients are ongoing and have been extensively reviewed recently¹⁶.

In the current report, we introduce the monoclonal antibody and the Fab fragment NT4X specific for N-truncated Aβ_4−x and Aβ_pE3-42 as an improved therapeutic entity for AD and study its effect in three mouse models. We also compared the treatment effect of the pan-pyroglutamate Aβ_3−x (1–57¹⁷) antibody, which has a similar plaque-binding profile like two other pyroglutamate Aβ_3−x specific antibodies used in preclinical trials^18,19 with the effect of NT4X in 5XFAD mice. The aim of the project was to explore whether Aβ_4−x is a relevant drug target in AD.

Results

NT4X binds N terminally truncated amyloid peptides

We have previously shown that the monoclonal antibody NT4X reacts with N-terminally truncated Aβ_pE3-40/42 and Aβ_4-40/42 variants, but not with Aβ_1–40/42 under denaturing and native conditions²⁰ and now confirm this binding profile with direct biophysical binding experiments using Biacore technology (Fig. 1). NT4X binds both Aβ_pE3-42 and Aβ_4-42 oligomers but not the full length 1-42 amyloid oligomers. Interestingly, if the peptides are allowed to aggregate over longer time periods, NT4X no longer binds (data not shown).

NT4X protects primary neurons from N terminally truncated amyloid peptide induced cell toxicity in vitro

In vitro assays were set up using primary rat cortical cultures to investigate the protective properties of the NT4X antibody against the various amyloid peptides. Concomitant with the binding properties of the antibody, NT4X rescues Aβ_pE3-42 and Aβ_4-42 oligomer induced toxicity but not of full-length Aβ_1-42 induced toxicity (Fig. 2).

In the current study, we used NT4X and its Fab fragment to elucidate their therapeutic potential in three Alzheimer mouse models.

Age-dependent spatial reference memory deficits in Tg4-42_hom mice

Memory deficits have previously been described in Tg4-42_hom mice at 8 months of age¹³. In order to identify the onset of spatial reference memory deficits Tg4-42_hom mice were analyzed at four, five, six and seven months (m) of age using the Morris water maze.

All mice showed progressively decreased escape latencies over three days of cued training (Fig. 3a; two-way repeated measures ANOVA, 4 m, 5 m, 6 m and 7 m: main effect of days: p < 0.0000001). All mice showed comparable swimming speeds (Fig. 3b).

Across the five days of acquisition training Tg4-42_hom mice, irrespective of age, showed a significant decrease in the escape latencies (Fig. 3c). For the escape latency a significant main effect of days could be found (two-way repeated measures ANOVA, days: p = 0.0000001). However, a significant difference was detected between the age groups (two-way repeated measures ANOVA, age: p = 0.000219). Four months old Tg4-42_hom mice performed significantly superior to 6-months-old mice on day 3 to 5 (one-way-ANOVA, day 3: p < 0.001; day 4 and 5: p < 0.01). Furthermore, 4-month-old mice showed significantly shorter escape latencies compared to 5- and 7-month-old mice on day 3 (one-way-ANOVA, p < 0.05).

48 hours after the last acquisition trial, a probe trial was conducted to assess spatial reference memory. At four months of age, Tg4-42_hom mice displayed a significant preference for the target quadrant, as indicated by the percentage time spent in the four quadrants of the pool (Fig. 3d, one-way ANOVA, 4m: p < 0.001 target vs. left and opposite quadrant, p < 0.01 target vs. right quadrant). Five months old Tg4-42_hom only spent a significant higher percentage of time in the target quadrant in comparison to the left and the opposite quadrant (one-way ANOVA, 5m: p < 0.05 target vs. left and opposite quadrant). Therefore, 5-month-old Tg4-42_hom mice showed early signs of impaired spatial reference memory. Moreover six and seven-month-old Tg4-42_hom mice displayed no significant preference for the target quadrant indicating severe spatial reference memory deficits.

A significant difference was detected between the age groups (two-way repeated measures ANOVA, age: p = 0.000219). Four months old Tg4-42_hom mice performed significantly superior to 6-months-old mice on day 3 to 5 (one-way-ANOVA, day 3: p < 0.001; day 4 and 5: p < 0.01). Furthermore, 4-month-old mice showed significantly shorter escape latencies compared to 5- and 7-month-old mice on day 3 (one-way-ANOVA, p < 0.05).

In summary, the results of the probe trial demonstrated that spatial reference memory deficits in Tg4-42_hom mice start at 5 months of age. Beginning at 6 months spatial reference memory in Tg4-42 mice is severely impaired.

Tg4-42_hom mice exhibit age-dependent progressive neuron loss in the CA1 layer of the hippocampus

The Tg4-42 transgenic mouse is one of the few transgenic Alzheimer models that exhibit significant neuron loss. Our previous work demonstrated an age- and gene-dose-dependent reduction of neurons in the CA1 layer of the hippocampus in Tg4-42 mice²⁰. At eight months stereology revealed a 38% neuron loss in hemizygous Tg4-42 mice compared to wild-type littermate controls. In homozygous Tg4-42 (Tg4-42_hom) mice the neuron loss was even more pronounced with a more than 60% decline¹³. To extend these findings and determine the progression of neuron loss, CA1 neurons of Tg4-42_hom were counted between three and eight months of age using design-based stereology (Fig. 4). Next to Tg4-42_hom wild-type mice were analyzed at three and eight months of age.

The hippocampal pyramidal cell layer quantification revealed an age-dependent neuron loss in Tg4-42_hom mice (Fig. 4, one-way ANOVA, age: p = 0.000001). At three and four months of age no significant difference in the number of neurons was detected between wild-type (3m: mean = 296,262; SEM ± 7,532) and Tg4-42_hom mice (3m: mean = 304,704; SEM ± 37,750; 4m: mean = 244,781; SEM ± 21320). However, 5-, 6-, 7- and 8-month-old homozygous mice displayed a significant neuron loss of 43%, 50%, 55% and 64%, respectively (one-way ANOVA: 5m: mean = 167,823; SEM ± 5,106, p < 0.001; 6m: mean = 153,340; SEM ± 2,686, p < 0.001; 7m: mean = 128,531; SEM ± 7,385, p < 0.001, 8m: mean = 105,388; SEM ± 16,960, p < 0.001). As expected, the neuron number of wild-type mice did not significantly change during aging (wild-type 8m: mean = 283,321; SEM ± 9,423).

These results suggest a progressive death of neurons in Tg4-42_hom mice that starts at four months and reaches ~64% loss of CA1 neurons by eight months of age. In summary, the results confirm and extend our previous work¹³. Our data indicate that neuron loss in Tg4-42_hom occurs even earlier than previously shown and appears to begin when mice are about four months old. As shown above, five month-old Tg4-42_hom mice show onset of spatial reference memory deficits with a clear effect at six months of age. Therefore, we started the therapeutic study in Tg4-42_hom mice at three months of age a time point before neuron loss or memory deficits were observed.

Full-length and Fab fragment of NT4X rescues spatial reference memory deficits in Tg4-42_hom mice

Severe spatial reference memory deficits in Tg4-42_hom were detected at 5 and 6 months of age (Fig. 3). Therefore, 6-month-old Tg4-42_hom mice that had received weekly injections with the full-length or Fab of NT4X-antibody, the IgG antibody and PBS for a period of 12 weeks were assessed using the Morris water maze and compared with untreated Tg4-42_hom mice.

Non-treated and treated Tg4-42_hom groups showed progressively decreased escape latencies in the cued training (two-way repeated measures ANOVA, days: p = 0.0000001; Fig. 5a). All mice showed comparable swimming speeds (Fig. 5b). However, non-treated Tg4-42_hom swam significantly slower than PBS- and IgG-injected mice on the third day of cued training (one-way ANOVA, PBS p < 0.05, IgG p < 0.01). The cued training revealed that all mice had an intact vision and appropriate motor abilities to swim.

All groups showed a significant decrease in the escape latencies over the five days of the acquisition training (two-way repeated measures ANOVA, days: p = 0.0000001, Fig. 5c).

No quadrant preference was found for non-treated, IgG- and PBS-injected Tg4-42_hom in the probe trial. Both full-length and Fab NT4X immunized Tg4-42_hom mice displayed a significant preference for the target quadrant, as indicated by the percentage time spent in different quadrants of the pool (Fig. 5d, one-way ANOVA, full-length NT4X: p < 0.001 target vs. right and opposite quadrant, p < 0.01 target vs. left quadrant; Fab NT4X: p < 0.001 target vs. left and opposite quadrant, p < 0.01 target vs. right quadrant). Therefore, both the full-length NT4X antibody and the Fab fragment of NT4X were able to rescue spatial reference memory deficits in 6-months-old Tg4-42_hom mice.

Full-length and Fab of NT4X decelerate neuron loss in Tg4-42_hom mice

In order to study the potential therapeutic effect of NT4X on the observed neuron loss in 6 months old Tg4-42_hom the neuron numbers in the CA1 were quantified using design-based stereology. The number of neurons was compared between 6-months-old Tg4-42_hom immunized with full-length NT4X or Fab NT4X and three same-aged control groups: untreated Tg4-42_hom mice; PBS injected Tg4-42_hom mice and mice injected with an IgG2b antibody as an isotype control. Stereology revealed a significant treatment effect (Fig. 6, one-way ANOVA, treatment: p = 0.000016). Following ANOVA, the individual groups were then analyzed using Bonferroni multiple comparisons. Compared to untreated, PBS injected and IgG injected mice, the neuron numbers in Tg4-42_hom were significantly increased after immunization with NT4X (Fig. 6; mean = 171,000; one-way ANOVA: SEM ± 3,414; NT4X vs NT: p < 0.01; NT4X vs PBS: p < 0.05; NT4X vs IgG: p < 0.001). In contrast, the number of neurons did not differ significantly between untreated (mean = 150,300; SEM ± 2,572), PBS injected (mean = 153,100; SEM ± 4,500) and IgG injected Tg4-42_hom mice (mean = 137,900; SEM ±6,555). NT4X immunized Tg4-42_hom mice displayed 13% more neurons in the CA1 layer of the hippocampus than non-treated mice. Furthermore, Fab injected mice (mean = 165,800; SEM ± 4,717) displayed significantly more neurons than IgG injected control mice. The neuron loss in 6-months-old full-length NT4X immunized mice was comparable to 4.5-months-old Tg4-42_hom mice, whereas the neuron loss in Fab-treated mice was comparable to 5-months-old untreated Tg4-42_hom mice.

Full-length and Fab NT4X rescue Aβ4-42 induced working memory deficits in wildtype mice

In order to study the therapeutic effects of NT4X and its Fab fragment in wild-type mice, the animals were intraventricularly injected with freshly prepared 50 pmol Aβ_4-42 and Aβ_4-42 in combination with the NT4X antibody or the Fab fragment, respectively. Working memory was assessed using the Y-maze (Fig. 7). The alternation rate was significantly reduced after injection of Aβ_4-42 reaching chance level (Fig. 7a,b, dashed line). In contrast, mice injected with Aβ_4-42 and 1 pmol NT4X antibody behaved like vehicle controls and learned well (compared to Aβ_4-42 injection; one-way ANOVA: p < 0.05). The alternation rate in mice treated with 10 pmol NT4X further increased (compared to Aβ_4-42 injection; one-way ANOVA: p < 0.01). Furthermore, mice treated with Aβ_4-42 and 10 pmol Fab NT4X also showed no deficits in working memory and behaved like the vehicle control (compared to Aβ_4-42 injection; one-way ANOVA: p < 0.01). Mice treated with only the NT4X antibody or its Fab fragment showed a similar alternation rate than mice treated with the vehicle control alone. Therefore, the NT4X antibody and its Fab fragment were able to rescue the learning deficits induced through Aβ_4-42 injection in a dose-dependent manner.

NT4X decreases plaque load in 5XFAD mice

Plaque pathology in 5XFAD mice starts between two and three months of age and increases massively with age²¹. In order to determine the effects of NT4X immunization on the Aβ deposition in 5XFAD mice, brain sections were stained with Thioflavin S (ThS), which selectively detects fibrillar Aβ deposits²². NT4X immunized mice showed significantly fewer ThS-positive fibrillar plaques in the cortex as compared to the PBS control group (Fig. 8a, one-way ANOVA, p < 0.05). To further characterize the nature of the deposited Aβ plaques, brain sections were immunostained with N- and C-terminus specific Aβ antibodies. The pan-pyroglutamate Aβ_3-x antibody 1–57 was used to explore a possible treatment effect targeting pyroglutamate Aβ_3-x. 1–57 immunized 5XFAD mice showed no reduced ThS positive plaque load in the cortex. NT4X immunized 5XFAD mice showed significantly fewer pyroglutamate Aβ plaques (Fig. 8b, one-way ANOVA p < 0.01) than the PBS control group. In contrast, 1–57 immunized 5XFAD mice showed no reduced plaque load in the cortex. Immunostaining with an anti-Aβ_x-40 antibody showed a reduced plaque burden in the cortex of NT4X immunized 5XFAD mice (Fig. 8c, one-way ANOVA, p < 0.05). Immunostaining with an anti-Aβ_1-X (Fig. 8d) and anti-Aβ_x-42 (Fig. 8e) antibody revealed no significant differences in the plaque load of NT4X or 1–57 immunized 5XFAD mice and the PBS control group. Thus, NT4X administration decreased fibrillar and total Aβ depositions, especially N-truncated pyroglutamate Aβ_3-x in the cortex of 5XFAD mice. Representative images of ThS and pyroglutamate Aβ_3-x plaque load is shown in Fig. 8f.

Soluble levels of Aβ_1-40, Aβ_1-42 and Aβ_pE3-42 were analysed by commercially available ELISAs in total brain extracts of 5XFAD mice (Table 1). Although the levels in the NT4X treated mice was lower for Aβ_1-42 and Aβ_pE3-42 the effect was not significant.

Table 1 ELISA of brain lysates after therapeutic treatment using the antibodies NT4X, 1–57 and of PBS injected controls

Full size table

Discussion

While it is known that N-truncated Aβ peptides are major constituents in the brain of Alzheimer patients⁸ the major focus was on the role of pyroglutamate Aβ_3-42. The possibility of N-truncated Aβ_4-42 as a drug target has been largely neglected. We have generated a monoclonal antibody, which binds to both Aβ_pE3-42 and Aβ_4-42 truncated N-terminal amyloid low molecular weight oligomers but not to full-length Aβ_1-42 and will protect primary neuronal cultures from toxicity induced by the N-truncated amyloid peptides but not from the full length amyloid peptide.

Expression of Aβ4-42 induces an age-dependent CA1 neuron loss and associated memory decline

Tg4-42 mice develop severe hippocampus neuron loss and spatial reference memory deficits¹³. The Tg4-42 model represents the first mouse model expressing exclusively N-truncated Aβ_4-42. In the present study we examined the exact onset of spatial reference memory loss and the associated number of degenerated neurons in homozygous Tg4-42 mice. Broadbent et al.²³ examined the relationship between hippocampal lesion size and spatial memory in rats. Spatial memory impairment started after bilateral dorsal hippocampal lesions that encompassed 30–50% total volume and as lesion size increased from 50% to 100% of total hippocampal volume, performance was similarly impaired. Moser et al.²⁴ claimed that only 20–40% of the total hippocampus is required for efficient spatial learning. These findings show that the hippocampus is important for spatial reference memory albeit a significant neuron loss can be compensated. Our findings are in good agreement with these observations. At five months of age, Tg4-42 mice displayed a 43% neuron loss and first but mild signs of spatial reference memory deficits. However, at six months of age, a significant loss in spatial reference memory performance was observed with a reduction of 50% of neurons. We therefore conclude that a loss of 50% CA1 neurons is critical for learning and memory performance.

Full-length and Fab NT4X mitigated neuron loss and rescued memory decline in Tg4-42 mice

The neuron loss in Tg4-42 mice starts very early with 17% loss at four months of age. This is an attractive time point for therapeutic intervention as the mice are still pre-symptomatic, capable of performing well in the Morris water maze task up to an age of five months. We therefore started the passive immunization treatment at three months for a period of 12 weeks. Full-length NT4X immunized Tg4-42 mice displayed significantly more neurons as compared to control groups, representing a gain of two month with concomitant rescue of functional spatial reference memory in the life of a 6 months old mouse.

Full-length and Fab NT4X rescued memory after acute exposure to Aβ4-42 oligomers

We have previously shown that intraventricular injection of Aβ_4-42 oligomers induced deficits in working memory in wild type mice¹³. In the present study, treatment with NT4X and its Fab fragment rescued the deficits in a dosage-dependent manner arguing for a direct neutralizing effect of the antibody to Aβ_4-42 oligomer toxicity. The use of ICV injected Aβ_4-42 oligomers is likely better reflecting the conditions found in AD brains in the vicinity of plaques strengthening the relevance of the potential therapeutic use of NT4X.

NT4X lowers plaque load in 5XFAD mice

Using mass spectrometric analysis, we could previously demonstrate that 5XFAD mice harboured the following Aβ peptides: Aβ_1-42, Aβ_4-42, Aβ_5-42, Aβ_pE3-42 and Aβ_3-42²⁵. In the present study we treated 5XFAD mice between five and 7.5 months of age. Passive immunization with NT4X lowered plaque load for distinct Aβ species. As NT4X reacts with both Aβ_4-x and Aβ_pE3-x²⁰ a decrease of Aβ_pE3-x positive plaques can be explained by direct binding to Aβ_pE3-x peptides. As an isotype control we used the IgG2b antibody 1–57, which detects plaque-born pan-Aβ_pE3-x¹⁷. As treating 5XFAD mice with 1–57 had no effect on Aβ_pE3-x levels, we speculate that this pan-pyroglutamate Aβ-specific antibody was absorbed by binding to existing plaques in the 5XFAD mice and was thereby neutralized. Alternatively, it could also be that NT4X lowered Aβ_pE3-x levels indirectly if Aβ_4-x would act as a seeding factor for Aβ_pE3-x peptides. In agreement with this explanation, we previously observed that intraneuronal Aβ_4-x preceded the appearance of Aβ_pE3-x in 5XFAD mice²⁰. Thioflavin-S-positive plaques and Aβ_x-40 plaques were also significantly reduced after NT4X treatment suggesting a treatment effect against soluble Aβ_x-40 aggregates either by direct binding of the antibody to the peptides or indirectly by influencing seeding Aβ species like Aβ_pE3-x as shown previously^25,26. NT4X does not bind Aβ_1-42 aggregates²⁰. Hence it can be explained why Aβ_1-x- and Aβ_x-42-positive plaque load was unchanged.

The treatment effects were only modest. One explanation could be that treatment was started after substantial plaque development. In addition, we would like to point out more forcefully that the “classic” AD mouse models are likely less than ideal models to study the pathogenic role of Aβ_4-x. Aβ_4-x is much less abundant in AD mouse models compared to AD patients (compare Portelius et al.¹¹ and Wittnam et al.²⁵, with mass spectrometry performed by the same group). The low abundance of Aβ_4-x in 5XFAD mice could be the simplest explanation why anti-Aβ_4-x immunotherapy might not yield spectacular effects in models such as 5XFAD. In addition, the 5XFAD model represents a typical model for familial AD producing primarily full-length Aβ_1-42^21,25, a situation not found in the brain of patients with sporadic AD⁸.

Mechanism of NT4X treatment effect and advantage of NT4X therapy

While it is evident that active or passive immunotherapy is effective in Alzheimer mouse models the mechanism of action remains elusive. Several hypothesis are currently being discussed⁸. Antibodies may act catalytically to dissolve preformed Aβ aggregates or prevent Aβ aggregation in the CNS²⁷. Microglia clearance of Aβ has also being considered²⁸. Intracranial administration of anti-Aβ antibodies into Tg2576 transgenic APP mice resulted in clearance of amyloid deposits and was associated with microglial activation²⁹. The Fc receptor of microglia may interact with the Fc part of the antibody bound to Aβ³⁰. On the contrary, using Fc receptor-gamma chain knock-out mice did not rescue plaque load in APP Tg2576 transgenic mice after passive immunization. Therefore, the Aβ-antibody treatment was not dependent on Fc receptor-mediated phagocytic³¹. Another therapeutic option does not even require the penetration of the blood brain barrier leading to the formulation of the peripheral sink hypothesis³². Chronic treatment with the monoclonal anti-Aβ antibody m266 led to increased plasma levels of Aβ and reduced amyloid plaques in the PDAPP transgenic mouse model. This hypothesis has been challenged by another study though. Yamada et al.³³ have reported that immunotherapy with m266 neutralizes intracerebral, rather than peripheral, soluble, monomeric forms of Aβ.

Soluble Aβ and plaque-bound levels do not necessarily correlate with therapeutic outcome. In a preclinical passive immunization study it has been possible to show reversal of memory deficits without reducing brain Aβ burden in an AD model³⁴. Passive immunization of APPswe/PS1ΔE9 transgenic mice with an antibody against the N-terminus of pyroglutamate Aβ_3-X significantly reduced total plaque deposition in hippocampus and cerebellum, however, Aβ levels measured by ELISA were not affected³⁵. De Mattos and colleagues¹⁹ reported that Aβ antibodies can have different mode of actions in clearing plaque load depending in their target engagement.

The antibody pool reaching the brain could have been neutralized by binding to amyloid plaques, which would lead to weakened efficiacy. This appeared to be the case when we injected antibody 1–57 in 5XFAD mice. This pan-pyroglutamate Aβ antibody detects abundant plaques in 5XFAD mice¹⁷. Furthermore, the use of antibodies targeting mainly plaques is now being regarded as a potential risk factor as plaques may serve as reservoirs of toxic Aβ peptides^4,6. The failure of Bapineuzumab in clinical trials³⁶ could at least be partly explained by the mobilization of toxic Aβ species from inert plaque material. Moreover, the crystal structure of a Bapineuzumab Fab-Aβ peptide complex revealed that it captured Aβ in a monomeric helical conformation at the N-terminus³⁷. The authors concluded that the crystal structure explains the antibody’s selectivity for monomeric Aβ species and that it cannot recognize N-terminally modified or truncated Aβ peptides. We showed that both full-length and the Fab fragment of NT4X rescued memory deficits in two mouse models for AD and mitigated neuron loss in the Tg4-42 model. As the Fab fragment lacks the Fc part of the antibody, we conclude that microglial FcR is not involved in neutralizing Aβ_4-42 and pyroglutamate Aβ_3-42. Overall, this report is the first to demonstrate the therapeutic potential of NT4X, an antibody recognizing two N-terminally truncated peptides Aβ_4-x and pyroglutamate Aβ_3-x in three mouse models for AD.

Material and Methods

Transgenic mice

The transgenic mouse lines Tg4-42 and 5XFAD used in this study have been described previously^13,21.

Cell culture and antibody purification

The NT4X hybridoma cell line (IgG2b; official name of cell line Aβ4–40 NT4X-167; DSM ACC3162) was cultured in a serum-free media for hybridoma culture ISF-1 (Biochrom) and maintained in fed batch/continuous perfusion mode at 25% Oxygen, 5% CO2 and 37 °C in a 3L glass vessel bioreactor (Applikon) controlled using ADI 1030 (Applikon). The cell-culture supernatants were harvested by centrifugation at 500 g and the media was collected. Media was further centrifuged at 10,000 g for 30 min prior to Protein A affinity chromatography and pH was stabilized by addition of 20% (v/v) of PBS buffer. Media was loaded at 5 ml/min onto HiTrap™ Protein A HP (GE Healthcare) connected to an AKTAxpress (GE Healtcare). Further column washing and elution was done according to Protein A column manufacturer instructions. The eluted sample was further purified by size-exclusion chromatography using a HiLoad 26/60 Superdex 200 pg run in PBS on an AKTAxpress (GE Healthcare). Fab fragments were produced utilizing papain digestion of the intact NT4X monoclonal antibody. Papain agarose (Sigma) was pre-activated, shaking at 1400 rpm, with 10 mM cysteine (Sigma) in PBS for 30 min at room temperature. Previously purified NT4X antibody (in PBS) was incubated for 4 hours at 37 °C with pre-activated papain agarose (1 U agarose/5 mg antibody). Papain agarose is subsequently removed by filtration through a 0.45 μm filter. Fab sample is further purified by size-exclusion chromatography using a HiLoad 26/60 Superdex 75 pg run in PBS on an AKTAxpress (GE Healthcare).

Biophysical binding studies: kinetic analysis of Aβ peptides binding to immobilised NT4X antibody

Surface Plasmon Resonance (SPR) analysis was performed at 25 °C using the Biacore T200 (GE Healthcare). Purified NT4X monoclonal antibody (0.2 ug/ml) was captured on a CM5 chip (to which an anti-mouse IgG antibody was immobilised) at a density of ~130 response units (RU) to study the binding kinetics with Aβ_1-42, Aβ_pE3-42 and Aβ_4-42. A plain CM5 surface, which was activated and blocked by ethanolamine was used as a reference surface. Binding experiments were performed using HBS-EP buffer (0.01 M HEPES, pH 7.4, 0.15 M NaCl, 3mM EDTA, 0.005% P20) as the running buffer. The binding sensorgrams were recorded by injecting different concentrations (125nM, 250nM, 500nM and 1000nM) of freshly prepared Aβ peptides in HBS-EP buffer for 5 min at a flow rate of 30μl/min over the immobilised NT4X antibody surface. The dissociation profile was monitored for 20 min and then the surface was regenerated with 10 mM glycine HCl at pH 1.7. To avoid any mass transfer effect, the experiments were performed at a high flow rate of 30 μl/min using freshly prepared Aβ peptides. Reference subtracted SPR data were evaluated with the Biacore T200 Evaluation Software (version 2.0) using a 1:1 Langmuir binding model.

Cell based neuroprotection assays

Neurones were prepared from the cortex of 18 day old embryonic CD rat brains using a papain digestion kit (Worthington, Biochemical Corporation). Cells were plated at 3 × 10⁵ cells/ml in 96 well Cell Coat, Poly-D-Lysine coated plates (Greiner) in Neurobasal media with Pen/Strep, L-glutamine and B27 supplement with antioxidants (Gibco, ThermoFisher). The plates were incubated in a humidified incubator at 37^oC, 5% CO₂ for two days prior to adding the antibodies and amyloid peptides. Media was removed from the plates and fresh Neurobasal media containing B27 supplement without antioxidants (Invitrogen) added to perform the assay. Purified antibody stocks (mouse NT4X IgG2b and an isotype control antibody) were diluted in sterile PBS (Ca/Mg free) and 10ul added to a total volume of 100 μl per well to give a series of dilutions at the required concentration. HFIP treated and dried amyloid peptide aliquots (stored in a desiccator at −80 °C) were dissolved in 100 mM NaOH and further diluted in Neurobasal media without antioxidants to achieve final peptide concentrations of 5 μM for both Aβ_pE3-42 and Aβ_1-42 and 10 μM for Aβ_4-42 peptide in the cell assay (Anaspec, Fremont, CA (Eurogentec) and California Peptide Research, San Francisco). The plates were incubated for seven days prior to LDH measurement with the CytoTox96 Non-Radioactive cytotoxicity assay kit (Promega). The LDH assay was performed on 50 μl/well culture supernatant in fresh 96 well assay plates (Costar). The plates were read at 490 nm on a Tecan Safire II plate reader. The inhibition assay was repeated n = 2 to 3 for each peptide with the two antibodies detailed.

Passive immunization against Aβ

The potential therapeutic effects of NT4X were studied using a passive immunization approach in Tg4-42_hom and 5XFAD mice.

Passive immunization was performed by intraperitoneal injections of NT4X or its Fab fragment²⁰ and compared to control groups using antibody of the same immunoglobulin class as NT4X (IgG2b) and PBS injections. Tg4-42_hom mice were immunized by injections of the NT4X antibody, 10 mg/kg body weight, diluted in sterile PBS (pH 7.4). Mice received weekly injections beginning at 3 months of age. Each mouse received a total of 12 injections. Behavior testing started between the ninth and the tenth injection. Animals were sacrificed after the last injection. Control groups comprised of Tg4-42_hom mice received intraperitoneal PBS injections or injections of IgG2b antibody (10 mg/kg body weight) diluted in PBS, respectively. Control mice were treated exactly the same as the NT4X group receiving 12 injection of the respective control solution starting at 3 months of age. A non-treated Tg4-42_hom group served as an additional control. Animals were sacrificed after the last injection at 6 months of age.

In addition, 5-month-old 5XFAD mice were weekly injected with NT4X (100 μl/10 g body weight, diluted in sterile PBS), 1–57 (IgG2b backbone¹⁷ against the N-terminus of pyroglutamate Aβ_3−x; 10 mg/kg body weight, diluted in sterile PBS) or PBS respectively. Each mouse received a total of 10 intraperitoneal injections. Behavior testing started between the 9^th and the 10^th injection. Animals were sacrificed after the last injection at 7.5 months of age.

Spatial reference memory by Morris water maze

Spatial reference memory in Tg4-42_hom mice was evaluated using the Morris water maze³⁸ as described previously¹³.

Quantification of neuron numbers using unbiased stereology

Stereological analysis was performed as previously described^13,39. The hippocampal cell layer CA1 (Bregma −1.22 to −3.52 mm) was delineated on cresyl violet-stained sections and analysed with a stereology workstation (Olympus BX51 with a motorized specimen stage for automatic sampling), StereoInvestigator 7 (MicroBrightField, Williston, USA) and a 100x oil lens (NA = 1.35).

Immunohistochemistry and histology

Mouse tissue samples were processed as described previously¹⁷. Aside from 1–57 (pyroglutamate Aβ_3-x, 1 mg/ml; 1:5000) the following antibodies were used: mouse monoclonal G2-10 (Aβ_X-40, Millipore, Schwalbach), rabbit polyclonal antibodies against Aβ₄₂ (Aβ_X-42, #218703, Synaptic Systems, Göttingen) and 82E10 (Aβ_1-x, 82E1; 1 μg/ml, IBL, Minneapolis, USA).

Quantification of Abeta load

Plaque load was quantified in NT4X immunized 5XFAD mice and control groups. For each animal, 5–6 paraffin embedded sections, which were at least 80 μm afar from each other, were stained simultaneously with DAB as chromogen. For Thioflavin S fluorescent staining tissue sections were deparaffinized and rehydrated, washed twice in deionized water and then treated with 1% (w/v) ThioflavinS in aqueous solution and counterstained in a 1% (w/v) aqueous solution of 4´6-diamidin-2-phenylindol. The relative Aβ load was evaluated in the frontal cortex using an Olympus BX-51 microscope equipped with an Olympus DP-50 camera and the ImageJ software (NIH, USA). Representative pictures of 100× magnification were systematically captured. Using ImageJ the pictures were binarized to 8-bit black and white pictures and a fixed intensity threshold was applied defining the DAB staining. Measurements were performed for a percentage area covered by DAB staining, as well as for the number of grains per mm² and the average size of the grains.

Abeta ELISA

Brains were homogenized in 8-fold amount of TBS Lysis Buffer (50 mM Tris, pH 8.0 supplemented with 1 tablet/10 ml of Complete Protease Inhibitor cocktail (Roche)) and homogenates were spun down for 20 min at 17.000× g, 4 °C in a stratos Biofuge (Thermo Fisher). Supernatant (termed ‘TBS fraction’) was separated. The pellet was resuspended in 1 ml TBS lysis buffer and spun down again. Supernatant was discarded and the pellet dissolved in SDS lysis buffer (2% SDS supplemented with 1 tablet/10 ml Cømplete Protease inhibitor cocktail) using a branson sonifier 150 (Hellmann) at power ′2′ with 10 single pulses. The lysate was spun down again as described above and the supernatant (termed ‘SDS-Fraction’) was separated. Total protein concentrations of both fractions were determined using the RotiQuant Protein Assay (Roth) with BSA as a standard. ELISA of Aβ was carried out in 96-well high-binding microtiter plates as follows. For Aβ_1-40/42, monoclonal antibody IC16⁴⁰ raised against residues Aβ_1-15 was used as a capture antibody (diluted in PBS pH 7.2) and incubated over night at 4 °C in a humid chamber. After removal of the capture antibody, brain lysate samples (100-fold diluted for Aβ_1-40; 1000-fold diluted for Aβ_1-42) were added. Antibodies specific for the C-terminal Aβ_x-40 or Aβx-42 epitope coupled to horseradish peroxidase diluted in PBS (pH 7.2, supplemented with 0.05% Tween 20, 1% BSA) were used as secondary antibodies and again incubated over night at 4 °C in a humid chamber. After three times washing with PBS (pH 7.2, supplemented with 0.05% Tween-20, 1% BSA), 50 μl of TMB ELISA peroxidase substrate (Interchim) was added and incubated for 1–10 min at RT in darkness. The reaction was stopped with 50 μl 2 M H₂SO₄ and absorbance was measured in a Paradigm microplate reader (Beckman Coulter) at 450 nm. For generation of standard curves, synthetic Aβ_1-40 and Aβ_1-42 peptides (JPT Peptide Technologies) freshly dissolved in DMSO at 10 μg/mL were used. Aβ_pE3-42 ELISA was performed using the Amyloid-beta (3pE-42) ELISA kit (JBL) according to the manufacturer´s instructions.

Intracerebroventricular injection of soluble Aβ

12-week-old male C57BL/6J mice (Janvier, Le Genest-St-Isle, France) were intracerebroventricularly (icv) injected under anesthetization. Freshly prepared Aβ_4-42 peptides [50 pmol in 1 μL; 0.1 M phosphate-buffered saline (pH 7.4)] or freshly prepared 50 pmol Aβ_4-42 followed 10 min by injecting the NT4X antibody or its Fab fragment [0.1 M phosphate-buffered saline (pH 7.4)] was injected into the right ventricle, with stereotaxic coordinates from the bregma (AP –0.22, L –1.0 and D 2.5 in mm). Vehicle (0.1 M phosphate-buffered saline) or vehicle in combination with 1 or 10 pmol NT4X was injected into the right ventricle as a control. icv injections were made using a 10-μl Hamilton microsyringe fitted with a 26-gauge needle. Four days following icv infusion of Aβ peptides, working memory was assessed using the Y-maze test.

Working memory by the Y-maze task

Immediate spatial working memory performance in ICV injected 12-week-old male C57BL/6J wild-type mice was assessed by recording spontaneous alternation behavior in a Y-maze as described previously^13,41,42.

Statistical analysis

Differences between groups were tested with one-way analysis of variance (ANOVA) followed by Bonferroni multiple comparisons, ANOVA followed by Dunnett’s multiple comparisons test or two-way repeated measures ANOVA as indicated. All data are given as means ± standard error of the mean (SEM) or standard deviation (SD) as indicated. Significance levels are given as follows: ***p < 0.001; **p < 0.01; *p < 0.05. All statistics were calculated using STATISTICA version 10.0 for Windows (StatSoft, Tulsa, OK, USA) and GraphPad Prism version 5.04 for Windows (GraphPad Software, San Diego, CA, USA).

Study approval

Animal experiments were approved by the local animal protection authorities (Niedersächisches landesamt für Verbraucherschutz und Lebensmittelsicherheit) under the approval number 14/1450. The experiments were conducted in accordance with the approved protocols.

Additional Information

How to cite this article: Antonios, G. et al. Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X. Sci. Rep. 5, 17338; doi: 10.1038/srep17338 (2015).

References

Selkoe, D. J. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer’s disease. Trends Cell Biol. 8, 447–453 (1998).
Article CAS PubMed Google Scholar
Selkoe, D. J. Alzheimer’s disease: genes, proteins and therapy. Physiol. Rev. 81, 741–766 (2001).
Article CAS PubMed Google Scholar
Klein, W. L. Abeta toxicity in Alzheimer’s disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41, 345–352 (2002).
Article CAS PubMed Google Scholar
Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 8, 101–112 (2007).
Article CAS PubMed Google Scholar
Wilcox, K., Lacor, P., Pitt, J. & Klein, W. Aβ Oligomer-Induced Synapse Degeneration in Alzheimer’s Disease. Cell. Mol. Neurobiol. 31, 939–948 (2011).
Article CAS PubMed PubMed Central Google Scholar
Benilova, I., Karran, E. & De Strooper, B. The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat. Neurosci. 29, 349–357 (2012).
Article Google Scholar
Jawhar, S., Wirths, O. & Bayer, T. A. Pyroglutamate Abeta-a hatchet man in Alzheimer disease. J. Biol. Chem. 286, 38825–38832 (2011).
Article CAS PubMed PubMed Central Google Scholar
Bayer, T. & Wirths, O. Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer’s disease. Acta Neuropathol. 127, 787–801 (2014).
Article CAS PubMed PubMed Central Google Scholar
Masters, C. L. et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. 82, 4245–4249 (1985).
Article ADS CAS PubMed PubMed Central Google Scholar
Lewis, H. et al. Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-β (42) peptide in vascular dementia. Neuropathol. Appl. Neurobiol. 32, 103–118 (2006).
Article CAS PubMed Google Scholar
Portelius, E. et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease. Acta Neuropathol. 120, 185–193 (2010).
Article CAS PubMed PubMed Central Google Scholar
Pike, C. J., Overman, M. J. & Cotman, C. W. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J. Biol. Chem. 270, 23895–23898 (1995).
Article CAS PubMed Google Scholar
Bouter, Y. et al. N-truncated amyloid beta (Abeta) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Acta Neuropathol. 126, 189–205 (2013).
Article CAS PubMed PubMed Central Google Scholar
Schenk, D. et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177 (1999).
Article ADS CAS PubMed Google Scholar
Morgan, D. et al. Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408, 982–985 (2000).
Article ADS CAS PubMed Google Scholar
Delrieu, J., Ousset, P. J., Caillaud, C. & Vellas, B. ‘Clinical trials in Alzheimer’s disease’: immunotherapy approaches. J. Neurochem. 120, 186–193 (2012).
Article CAS PubMed Google Scholar
Wirths, O. et al. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases. J. Neural Transm. 117, 85–96 (2010).
Article CAS PubMed Google Scholar
Frost, J. L. et al. Pyroglutamate-3 amyloid-beta deposition in the brains of humans, non-human primates, canines and Alzheimer disease-like transgenic mouse models. Am. J. Pathol. 183, 369–381 (2013).
Article CAS PubMed PubMed Central Google Scholar
Demattos, R. B. et al. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer’s disease mice. Neuron 76, 908–920 (2012).
Article CAS PubMed Google Scholar
Antonios, G. et al. N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody. Acta Neuropathol. Commun. 1, 56, 10.1186/2051-5960-1-56 (2013).
Article PubMed PubMed Central Google Scholar
Oakley, H. et al. Intraneuronal beta-Amyloid Aggregates, Neurodegeneration and Neuron Loss in Transgenic Mice with Five Familial Alzheimer’s Disease Mutations: Potential Factors in Amyloid Plaque Formation. J. Neurosci. 26, 10129–10140 (2006).
Article CAS PubMed PubMed Central Google Scholar
Bussiere, T. et al. Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive A{beta} Immunotherapy on Their Clearance. Am. J. Pathol. 165, 987–995 (2004).
Article CAS PubMed PubMed Central Google Scholar
Broadbent, N. J., Squire, L. R. & Clark, R. E. Spatial memory, recognition memory and the hippocampus. Proc. Natl. Acad. Sci. USA 101, 14515–14520 (2004).
Article ADS CAS PubMed PubMed Central Google Scholar
Moser, M. B., Moser, E. I., Forrest, E., Andersen, P. & Morris, R. G. Spatial learning with a minislab in the dorsal hippocampus. Proc. Natl. Acad. Sci. USA 92, 9697–9701 (1995).
Article ADS CAS PubMed PubMed Central Google Scholar
Wittnam, J. L. et al. Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. J. Biol. Chem. 287, 8154–8162 (2012).
Article CAS PubMed PubMed Central Google Scholar
Schilling, S. et al. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer’s disease-like pathology. Nat. Med. 14, 1106–1111 (2008).
Article CAS PubMed Google Scholar
Solomon, B., Koppel, R., Frankel, D. & Hanan-Aharon, E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. USA 94, 4109–4112 (1997).
Article ADS CAS PubMed PubMed Central Google Scholar
Wang, A., Das, P., Switzer, R. C., 3rd, Golde, T. E. & Jankowsky, J. L. Robust amyloid clearance in a mouse model of Alzheimer’s disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J. Neurosci. 31, 4124–4136 (2011).
Article CAS PubMed PubMed Central Google Scholar
Wilcock, D. M. et al. Intracranially administered anti-Αβ antibodies reduce β-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 23, 3745–3751 (2003).
Article CAS PubMed PubMed Central Google Scholar
Bard, F. et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916–919 (2000).
Article CAS PubMed Google Scholar
Das, P. et al. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma−/− knock-out mice. J. Neurosci. 23, 8532–8538 (2003).
Article CAS PubMed PubMed Central Google Scholar
DeMattos, R. B. et al. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 98, 8850–8855 (2001).
Article ADS CAS PubMed PubMed Central Google Scholar
Yamada, K. et al. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J. Neurosci. 29, 11393–11398 (2009).
Article CAS PubMed PubMed Central Google Scholar
Dodart, J. C. et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease model. Nat. Neurosci. 5, 452–457 (2002).
Article CAS PubMed Google Scholar
Frost, J. L. et al. Passive immunization against pyroglutamate-3 amyloid-beta reduces plaque burden in Alzheimer-like transgenic mice: a pilot study. Neurodegener. Dis. 10, 265–270 (2012).
Article CAS PubMed PubMed Central Google Scholar
Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 370, 322–333 (2014).
Article CAS PubMed PubMed Central Google Scholar
Miles, L. A., Crespi, G. A. N., Doughty, L. & Parker, M. W. Bapineuzumab captures the N-terminus of the Alzheimer’s disease amyloid-beta peptide in a helical conformation. Sci. Rep. 3, 1302, 10.1038/srep01302 (2013).
Article ADS CAS PubMed PubMed Central Google Scholar
Morris, R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11, 47–60 (1984).
Article CAS PubMed Google Scholar
Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T. A. & Wirths, O. Motor deficits, neuron loss and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer’s disease. Neurobiol. Aging 33, 196.e129–196.e140, 10.1016/j.neurobiolaging.2010.05.027 (2012).
Article CAS Google Scholar
Hahn, S. et al. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer’s disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure. J. Neurochem. 116, 385–395 (2011).
Article CAS PubMed Google Scholar
Youssef, I. et al. N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis. Neurobiol. Aging 29, 1319–1333 (2008).
Article CAS PubMed Google Scholar
Sarter, M., Bodewitz, G. & Stephens, D. N. Attenuation of scopolamine-induced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology 94, 491–495 (1988).
Article CAS PubMed Google Scholar

Download references

Acknowledgements

We thank Oliver Wirths and Petra Tucholla for excellent technical help and greatly acknowledge the financial support by the Studienstiftung des deutschen Volkes, the Jacob Henle Program for Experimental Medicine, the U4 Graduate School, the Erasmus Mundus Program MEDASTAR and the Alzheimer Forschung Initiative.

Author information

Antonios Gregory and Borgers Henning contributed equally to this work.

Authors and Affiliations

Department of Psychiatry and Psychotherapy, Division of Molecular Psychiatry, Georg-August-University Göttingen, University Medicine Göttingen, 37075, Göttingen, Germany
Gregory Antonios, Henning Borgers, Bernhard C. Richard, Andreas Brauß, Julius Meißner, Yvonne Bouter & Thomas A. Bayer
Department of Neuropathology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
Sascha Weggen
Macromolecular Crystallography, Max-Planck Institute of Biophysical Chemistry (MPI-BPC), 37077, Göttingen, Germany
Vladimir Pena
SynAging, 54000, Nancy, France
Thierry Pillot
Medical Research Council Technology, 1-3 Burtonhole Lane, NW7 1AD, London, UK
Sarah L. Davies, Preeti Bakrania, David Matthews & Janet Brownlees

Authors

Gregory Antonios
View author publications
You can also search for this author in PubMed Google Scholar
Henning Borgers
View author publications
You can also search for this author in PubMed Google Scholar
Bernhard C. Richard
View author publications
You can also search for this author in PubMed Google Scholar
Andreas Brauß
View author publications
You can also search for this author in PubMed Google Scholar
Julius Meißner
View author publications
You can also search for this author in PubMed Google Scholar
Sascha Weggen
View author publications
You can also search for this author in PubMed Google Scholar
Vladimir Pena
View author publications
You can also search for this author in PubMed Google Scholar
Thierry Pillot
View author publications
You can also search for this author in PubMed Google Scholar
Sarah L. Davies
View author publications
You can also search for this author in PubMed Google Scholar
Preeti Bakrania
View author publications
You can also search for this author in PubMed Google Scholar
David Matthews
View author publications
You can also search for this author in PubMed Google Scholar
Janet Brownlees
View author publications
You can also search for this author in PubMed Google Scholar
Yvonne Bouter
View author publications
You can also search for this author in PubMed Google Scholar
Thomas A. Bayer
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

G.A., performed experiments, analyzed data, contributed to experimental design and to manuscript preparation. B.C.R., H.B., S.D. and P.B. performed experiments, analyzed data and contributed to manuscript preparation. A.B. and J.M. performed experiments. Y.B. performed experiments, analyzed data and contributed to experimental design and to manuscript preparation. S.W., T.P. and V.P. analyzed data. D.M. and J.B. designed experiments, supervised experiments and contributed to the writing of the manuscript. T.A.B. designed the studies analyzed data, supervised experiments, designed the entire project and wrote the manuscript. All authors discussed the results, read and approved the final manuscript.

Ethics declarations

Competing interests

The antibody NT4X and the animal model Tg4-42 are subject of patent applications.

Rights and permissions

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Reprints and permissions

About this article

Cite this article

Antonios, G., Borgers, H., Richard, B. et al. Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X. Sci Rep 5, 17338 (2015). https://doi.org/10.1038/srep17338

Download citation

Received: 16 June 2015
Accepted: 28 October 2015
Published: 02 December 2015
DOI: https://doi.org/10.1038/srep17338

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.